At 3 and 12 months post-index, however, the 1.0 mg dosage formulation was the most common (53% and 67%, respectively), followed by 0.5 mg (39% and 29%, respectively)
Fatigue or headaches Rare but can occur in individuals sensitive to peptides affecting metabolic pathways
it may only be used lawfully within an authorised clinical trial or MHRA-regulated framework
It tells your brain you're full, slows digestion so you stay satisfied longer, and helps regulate blood sugar levels
Add electrolyte support (sodium, magnesium, potassium) for balance
When tirzepatide activates GLP-1 receptors, it stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is released only when blood glucose levels are elevated